Iovance Biotherapeutics Inc (IOVA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.59B
Last updated: Nov 17, 2026 at 4:35 PM ET
Iovance Biotherapeutics Inc (IOVA) Stock Chart
Iovance Biotherapeutics (IOVA) has a latest price of $7.53 on Nov 17, 2026, 51.0% below its 52-week high of $15.37. Its price rose 204.9% over the past 12 months. The month-end price rose 35.7% over the 10 years through Oct 2026, a compound annual rate of 3.1%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $46.40 in Dec 2020 and its lowest $1.72 in Jun 2025, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart IOVA with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for IOVA.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 5.8%, and over 6 months it rose 117.6%. The month-end price rose 122.0% over the 3 years through Oct 2026, a compound annual rate of 30.5%.
| Period | Change |
|---|---|
| 1 month | -47.0% |
| 3 months | -5.8% |
| 6 months | +117.6% |
| 12 months | +204.9% |
| 12 months, with dividends | +204.9% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +122.0% | +30.5% |
| 5 years | -65.1% | -19.0% |
| 10 years | +35.7% | +3.1% |
Price by Year
Its best calendar year was 2019, when the price rose 212.8%, and its weakest was 2022, when it fell 66.5%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $8.48 | +210.6% |
| 2025 | $2.73 | -63.1% |
| 2024 | $7.40 | -9.0% |
| 2023 | $8.13 | +27.2% |
| 2022 | $6.39 | -66.5% |
| 2021 | $19.09 | -58.9% |
| 2020 | $46.40 | +67.6% |
| 2019 | $27.68 | +212.8% |
| 2018 | $8.85 | +10.6% |
| 2017 | $8.00 | +15.1% |
Trading Range
The price is 33.3% below its 50-day average of $11.29 and 22.2% above its 200-day average of $6.16.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $7.53 | |
| 52-week high | $15.37 | -51.0% |
| 52-week low | $2.08 | +262.0% |
| 50-day average | $11.29 | -33.3% |
| 200-day average | $6.16 | +22.2% |
Price Risk
Over 3 years, its largest fall from a peak was 90.5%.
| Measure | Value |
|---|---|
| 1-year beta | 1.63 |
| Largest fall, 1 year | -49.3% |
| Largest fall, 3 years | -90.5% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About IOVA
What is IOVA's 1-year price change?
Iovance Biotherapeutics's price rose 204.9% over the past 12 months. With dividends included, the 12-month total return was 204.9%.
What is IOVA's 5-year price change?
Iovance Biotherapeutics's month-end price fell 65.1% over the 5 years through Oct 2026, a compound annual decline of 19.0%. These figures leave out dividends.
What is IOVA's 52-week high and low?
Iovance Biotherapeutics's 52-week high is $15.37 and its 52-week low is $2.08. Its latest price of $7.53 on Nov 17, 2026 is 51.0% below the high.
What is IOVA's beta?
Iovance Biotherapeutics's 1-year beta against the S&P 500 is 1.63, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 49.3%.
Is the IOVA chart free?
Yes. Advanced Charting for IOVA is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
IOVA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors, Government Contracts